Pricing Log in Create free account

Arcus Biosciences, Inc. (RCUS) vs Zai Lab Limited Unsponsored ADR (ZLAB)

Arcus Biosciences, Inc. and Zai Lab Limited Unsponsored ADR are both Biotechnology companies. Arcus Biosciences, Inc. and Zai Lab Limited Unsponsored ADR are of similar size ($2.9B and $2.7B). Zai Lab Limited Unsponsored ADR grew revenue faster over the last twelve months: 5.10% against −55.3%. Zai Lab Limited Unsponsored ADR has the higher net margin (−41.9% vs −393.2%) and the lower return on invested capital (−129.3% vs 0.00%). Across the 18 metrics below, Zai Lab Limited Unsponsored ADR leads on 13 and Arcus Biosciences, Inc. on 5.

Valuation

Metric RCUS ZLAB Biotechnology median
P/E n/m n/m 8.50
P/S 23.84 5.78 9.71
P/B 6.01 4.28 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 18.70 4.71 9.21
Earnings yield (17.63%) (7.35%) (33.15%)
Free cash flow yield (17.07%) (6.25%) (25.50%)

Profitability

Metric RCUS ZLAB Biotechnology median
Gross margin 100.00% 56.47% 65.16%
Operating margin (415.38%) (58.74%) 0.00%
Net margin (393.16%) (41.86%) 0.00%
Free cash flow margin (405.13%) (36.13%) 0.00%
Return on equity (90.82%) (26.91%) (56.36%)
Return on assets (46.02%) (16.81%) (48.04%)
Return on invested capital 0.00% (129.34%) 0.00%

Growth

Metric RCUS ZLAB Biotechnology median
Revenue growth (TTM) (55.34%) 5.10% 6.02%
EPS growth (last fiscal year) (4.78%) 38.46% 30.26%
Revenue growth, 5-year CAGR 25.93% 56.54% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RCUS ZLAB Biotechnology median
Debt to equity 0.22 0.39 0.00
Current ratio 3.82 2.13 4.72
Net debt to EBITDA 2.27 2.66 0.96

Dividend

Metric RCUS ZLAB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric RCUS ZLAB Biotechnology median
Market cap 2.91b 2.65b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack